Results for: Prostate

12 Trials Avaliable

  • GU 168

    A phase 1, open-label, dose escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer who have progressed on at least two prior systemic therapies

  • GU 178

    A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28)WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

  • GU 180

    A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer

  • GU 182

    A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • GU 190

    A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)

  • GU 207

    A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies

  • GU 208

    A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer

  • GU 209

    A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

  • GU 210

    CYCLONE 3 (I3Y-MC-JPEG): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone plus Prednisone with or without Abemaciclib in Patient with High-Risk Metastatic Hormone-Sensitive Prostate Cancer

  • GU 216

    A Phase 1/2, Open-label, Multi-Center Study of Dually ArmoredChimeric Antigen Receptor (CAR) T-cells (TmPSMA-02) in Patientswith Metastatic Castration Resistant Prostate Cancer (mCRPC)

  • GU 219

    A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate SpecificMembrane Antigen (PSMA), for Advanced Stage Prostate Cancer

  • RM 557

    A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)